CA3246964A1 - PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING OR TREATMENT OF A SYMPTOM ASSOCIATED WITH A PSEUDOALLEGIC REACTION - Google Patents

PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING OR TREATMENT OF A SYMPTOM ASSOCIATED WITH A PSEUDOALLEGIC REACTION

Info

Publication number
CA3246964A1
CA3246964A1 CA3246964A CA3246964A CA3246964A1 CA 3246964 A1 CA3246964 A1 CA 3246964A1 CA 3246964 A CA3246964 A CA 3246964A CA 3246964 A CA3246964 A CA 3246964A CA 3246964 A1 CA3246964 A1 CA 3246964A1
Authority
CA
Canada
Prior art keywords
acetamide
sulfamoylphenyl
phenyl
chlorophenyl
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3246964A
Other languages
English (en)
French (fr)
Inventor
Isao Matsuoka
Masa-Aki Ito
Kazuki Yoshida
Toshiyasu Imai
Original Assignee
Takasaki University Of Health And Welfare
Nippon Chemiphar Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takasaki University Of Health And Welfare, Nippon Chemiphar Co Ltd filed Critical Takasaki University Of Health And Welfare
Publication of CA3246964A1 publication Critical patent/CA3246964A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3246964A 2022-03-31 2023-03-30 PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING OR TREATMENT OF A SYMPTOM ASSOCIATED WITH A PSEUDOALLEGIC REACTION Pending CA3246964A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022060261 2022-03-31
JP2022-060261 2022-03-31
PCT/JP2023/013084 WO2023190826A1 (ja) 2022-03-31 2023-03-30 偽アレルギー反応に伴う症状の予防若しくは抑制又は治療用の医薬組成物

Publications (1)

Publication Number Publication Date
CA3246964A1 true CA3246964A1 (en) 2025-07-09

Family

ID=88202752

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3246964A Pending CA3246964A1 (en) 2022-03-31 2023-03-30 PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING OR TREATMENT OF A SYMPTOM ASSOCIATED WITH A PSEUDOALLEGIC REACTION

Country Status (7)

Country Link
US (1) US20260000678A1 (https=)
EP (1) EP4501357A1 (https=)
JP (1) JPWO2023190826A1 (https=)
CN (1) CN119233829A (https=)
AU (1) AU2023244778A1 (https=)
CA (1) CA3246964A1 (https=)
WO (1) WO2023190826A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025205829A1 (ja) * 2024-03-26 2025-10-02 国立研究開発法人国立循環器病研究センター 脳動脈瘤の予防又は治療用の医薬組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2397480T3 (da) 2009-02-16 2013-09-02 Nippon Chemiphar Co Diazepindionderivat
JP6207399B2 (ja) 2012-01-13 2017-10-04 日本ケミファ株式会社 Ｐ２ｘ４受容体拮抗剤
EP3020707B1 (en) 2013-07-12 2019-08-21 Nippon Chemiphar Co., Ltd. P2x4 receptor antagonist
AU2015296135A1 (en) 2014-08-01 2017-02-16 The Johns Hopkins University MrgprX2/MrgprB2 expressing cell based assay to detect pseudo-allergic drug reactions and to identify blockers to prevent the adverse reactions
US20180338980A1 (en) 2015-06-10 2018-11-29 Bayer Pharma Aktiengesellschaft Aromatic sulfonamide derivatives
PL3458443T3 (pl) 2016-05-03 2021-03-08 Bayer Pharma Aktiengesellschaft Aromatyczne pochodne sulfonamidowe
CA3186937A1 (en) 2020-08-03 2022-02-10 Isao Matsuoka Pharmaceutical composition for preventing, suppressing, or treating symptoms associated with allergic reaction

Also Published As

Publication number Publication date
WO2023190826A1 (ja) 2023-10-05
US20260000678A1 (en) 2026-01-01
JPWO2023190826A1 (https=) 2023-10-05
CN119233829A (zh) 2024-12-31
AU2023244778A1 (en) 2024-10-17
EP4501357A1 (en) 2025-02-05

Similar Documents

Publication Publication Date Title
US8921357B2 (en) Pyridazinone derivatives
US9221806B2 (en) 2-(heterocyclylbenzyl)pyridazinone derivatives
CN1898209A (zh) 葡糖激酶调节剂吡啶羧酸衍生物
CN101039677A (zh) 利用a2b腺苷受体拮抗剂预防和治疗气道重建及肺部炎症的方法
CN1898205A (zh) 吲哚满酮衍生物及其在治疗疾病状态如癌症中的用途
CN1934100A (zh) 取代喹唑啉或吡啶并嘧啶衍生物
CN1575284A (zh) 作为激酶抑制剂的取代的三唑二胺衍生物
CN1788000A (zh) 酞嗪酮衍生物
CN1056879A (zh) 吡咯衍生物及其制备方法
CN1711094A (zh) Src家族非受体酪氨酸激酶抑制剂和吉西他滨的组合产品
CN1471393A (zh) 神经性和神经心理性疾病的治疗方法
CN1886377A (zh) 用作葡糖激酶(glk)激活剂的苯甲酰基氨基吡啶基羧酸衍生物
CN1856327A (zh) Vegf受体抑制剂与化疗剂的组合
TW200804303A (en) Pyridazinone derivatives
CN101039915A (zh) 用于治疗ⅱ型糖尿病和肥胖症的苯氧基苯甲酰胺化合物
CN1882588A (zh) A2b腺苷受体拮抗剂
ES2396301T3 (es) Derivados de piridazinona
CN1960726A (zh) 包含jnk抑制剂和环孢菌素的组合物
CN1520314A (zh) 含有食糜酶抑制剂和ace抑制剂作为有效成分的药物
AU2021320957B2 (en) Pharmaceutical composition for preventing, suppressing, or treating symptom associated with allergic reaction
CN1950085A (zh) 作为趋化因子受体调节剂的3－(4－杂芳基环己基氨基)环戊烷羧酰胺
CN1726207A (zh) 取代的1－哌啶－4－基－4－吡咯烷－3－基哌嗪衍生物及其作为神经激肽拮抗剂的用途
US20260000678A1 (en) Pharmaceutical composition for preventing, suppressing, or treating symptom associated with pseudo-allergic reaction
CN1784232A (zh) 包含抗血管生成剂和Src抑制剂的联合的治疗药物及其治疗用途
CN101076331A (zh) 包含烟酸受体部分促效剂的用于治疗发红和脂质相关病症的组合物

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240926

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241010

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241010

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20241011

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241119

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241121

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20241121

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20241213

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20241213

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION)

Effective date: 20250709

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260108

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260108

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260423